Tracking baby health when moms take a special medication
NCT ID NCT06299748
Summary
This study aims to understand the safety of the medication efgartigimod during pregnancy and breastfeeding. It will follow women with conditions like myasthenia gravis who were exposed to the drug around conception, during pregnancy, or while nursing. Researchers will track pregnancy outcomes, infant health, and development to gather safety information.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITINGRoma, 00168, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikum der Ruhr-Universität Bochum St. Josef Hospital Neurologische Interdisziplinäre Infusionsambulanz + MS Studienambulanz (Haus E Ebene1)
RECRUITINGBochum, 44791, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
United BioSource LLC
RECRUITINGMorgantown, West Virginia, 26508, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.